Jefferies Financial Group Weighs in on Alexion Pharmaceuticals, Inc.’s FY2020 Earnings (NASDAQ:ALXN)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) – Investment analysts at Jefferies Financial Group dropped their FY2020 earnings estimates for Alexion Pharmaceuticals in a report released on Wednesday, October 16th. Jefferies Financial Group analyst E. Yang now forecasts that the biopharmaceutical company will post earnings of $8.74 per share for the year, down from their prior forecast of $8.90.

Other research analysts have also issued research reports about the company. Credit Suisse Group cut their price objective on Alexion Pharmaceuticals from $154.00 to $146.00 and set an “outperform” rating for the company in a research report on Friday, September 6th. Royal Bank of Canada restated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 18th. BMO Capital Markets began coverage on Alexion Pharmaceuticals in a research report on Thursday, September 12th. They set an “outperform” rating and a $149.00 price objective for the company. William Blair began coverage on Alexion Pharmaceuticals in a research report on Thursday, September 26th. They set an “outperform” rating and a $146.00 price objective for the company. Finally, Stifel Nicolaus restated a “hold” rating on shares of Alexion Pharmaceuticals in a research report on Friday, August 30th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $159.76.

Shares of Alexion Pharmaceuticals stock opened at $99.28 on Monday. The firm has a market cap of $22.07 billion, a price-to-earnings ratio of 14.00, a PEG ratio of 0.96 and a beta of 1.67. The business has a 50-day moving average price of $101.61 and a 200-day moving average price of $118.10. The company has a quick ratio of 3.56, a current ratio of 4.04 and a debt-to-equity ratio of 0.26. Alexion Pharmaceuticals has a twelve month low of $92.56 and a twelve month high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.51. The firm had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.18 billion. Alexion Pharmaceuticals had a return on equity of 20.23% and a net margin of 29.64%. The business’s quarterly revenue was up 15.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.07 earnings per share.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALXN. United Bank bought a new stake in Alexion Pharmaceuticals in the first quarter worth about $929,000. Amundi Pioneer Asset Management Inc. lifted its stake in Alexion Pharmaceuticals by 15.8% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 811,367 shares of the biopharmaceutical company’s stock worth $109,681,000 after purchasing an additional 110,593 shares during the last quarter. Nordea Investment Management AB lifted its stake in Alexion Pharmaceuticals by 199.3% in the first quarter. Nordea Investment Management AB now owns 36,102 shares of the biopharmaceutical company’s stock worth $4,881,000 after purchasing an additional 24,041 shares during the last quarter. Boltwood Capital Management bought a new stake in Alexion Pharmaceuticals in the second quarter worth about $921,000. Finally, Private Trust Co. NA lifted its stake in Alexion Pharmaceuticals by 3.6% in the second quarter. Private Trust Co. NA now owns 16,054 shares of the biopharmaceutical company’s stock worth $2,102,000 after purchasing an additional 560 shares during the last quarter. Institutional investors own 93.26% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Read More: How interest rates affect municipal bond prices

Earnings History and Estimates for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit